- Home
- CRBP vs FORR Comparison
CRBP vs FORR Comparison
Compare CRBP & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- FORR
- Stock Information
- Founded
- CRBP 2009
- FORR 1983
- Country
- CRBP United States
- FORR United States
- Employees
- CRBP N/A
- FORR N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- FORR Diversified Commercial Services
- Sector
- CRBP Health Care
- FORR Consumer Discretionary
- Exchange
- CRBP Nasdaq
- FORR Nasdaq
- Market Cap
- CRBP 210.8M
- FORR 169.1M
- IPO Year
- CRBP N/A
- FORR 1996
- Fundamental
- Price
- CRBP $11.23
- FORR $7.14
- Analyst Decision
- CRBP Strong Buy
- FORR
- Analyst Count
- CRBP 9
- FORR 0
- Target Price
- CRBP $48.38
- FORR N/A
- AVG Volume (30 Days)
- CRBP 546.2K
- FORR 128.8K
- Earning Date
- CRBP 11-12-2025
- FORR 10-30-2025
- Dividend Yield
- CRBP N/A
- FORR N/A
- EPS Growth
- CRBP N/A
- FORR N/A
- EPS
- CRBP N/A
- FORR N/A
- Revenue
- CRBP N/A
- FORR $403,871,000.00
- Revenue This Year
- CRBP N/A
- FORR N/A
- Revenue Next Year
- CRBP $220.00
- FORR $1.04
- P/E Ratio
- CRBP N/A
- FORR N/A
- Revenue Growth
- CRBP N/A
- FORR N/A
- 52 Week Low
- CRBP $4.64
- FORR $6.62
- 52 Week High
- CRBP $20.56
- FORR $17.65
- Technical
- Relative Strength Index (RSI)
- CRBP 38.90
- FORR 39.94
- Support Level
- CRBP $10.88
- FORR $7.38
- Resistance Level
- CRBP $12.43
- FORR $7.88
- Average True Range (ATR)
- CRBP 0.76
- FORR 0.37
- MACD
- CRBP 0.05
- FORR 0.00
- Stochastic Oscillator
- CRBP 51.59
- FORR 35.62
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.